investor_presentation
Atomera
Loading viewer...
investor_presentation
Format: PDF investor_presentation
POINT Biopharma Global Inc. presents its next-generation radioligands platform for cancer treatment, including clinical-stage programs PNT2002 (prostate cancer) and PNT2003 (neuroendocrine tumors) with partnerships generating up to $1.8B in milestone and royalty payments. The company operates a state-of-the-art GMP manufacturing facility and maintains a cash runway into 2026 with $435M in liquidity.
investor_presentation
67 Pages
investor_presentation
28 Pages
Molson Coors Beverage Company
investor_presentation
Atomera
Forth Corporation Year End 2022 Opportunity Day Presentation
investor_presentationinvestor_presentation
51 Pages
Forth Corporation Public Company Limited
Xperi TiVo Merger: Consumer Entertainment Technology IP Licensing
investor_presentationinvestor_presentation
20 Pages
Xperi Corporation and TiVo Corporation